Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events.

ABSTRACT:

Introduction

Venous thromboembolism (VTE) and arterial thrombotic (AT) events are a striking feature of severe COVID-19, however, relationship of remdesivir use and the risk of thrombotic events is unknown and has not been investigated before.

Methods

We retrospectively analyzed a cohort of 876 consecutive hospitalized severe and critical COVID-19 patients who were treated with remdesivir and compared them to 876 case-matched control patients. All patients were treated in our tertiary-level institution in period from 10/2020 to 6/2021. VTE and AT were diagnosed by objective imaging and laboratory methods.

Results

After exclusion of 71 VTE and 37 AT events present at the time of hospital admission, there were a total of 70 VTE (35 in the remdesivir and 35 in the contro

SUBMITTER: Lucijanic M 

PROVIDER: S-EPMC10170894 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature